Clinical Data

iStent® Clinical Data

Recent randomized controlled trials and case studies have shown that iStent® is a procedure with limited complications and an excellent safety profile. A recent independent international clinical study, published by the Journal of Cataract and Refractive Surgery, shows that iStent® provided a 36% reduction in IOP and an 86% reduction in the number of glaucoma medications three years following surgery.

Reduced Intraocular Pressure (IOP)

The U.S. IDE pivotal study for iStent® conducted by Glaukos and reviewed by the FDA was the first prospective, randomized U.S. IDE trial for a glaucoma device. This groundbreaking study showed that 68% of subjects in the iStent® treatment group (combined cataract and iStent® implantation) met the primary endpoint of IOP ≤ 21 mm Hg with no medications at 12 months, compared to only 50% of subjects in the cataract surgery group only. This difference is statistically (p = .004) and clinically significant.

Percentage of Patients With Sustained IOP ≤21% mm Hg Without Medication Use

In a second, independent, 36-month study, 79% of patients who received iStent® during a cataract procedure sustained target IOPs of ≤ 21 mm Hg.

Mean IOP

 
Important Safety Information »

Reduction in Glaucoma Medication

The IDE pivotal trial additionally showed 64% of patients who received iStent® remained medication free while sustaining a mean IOP reduction of 20% versus only 47% who underwent cataract surgery alone (p = .010).

chart3

In the independent, 36-month study noted previously, 74% of patients who received iStent® during a cataract procedure were able to stop taking their glaucoma medication after surgery.

Mean Meds

 
Important Safety Information »

Safety

For patients with combined cataract and open-angle glaucoma, iStent® can reduce IOP, while maintaining an excellent safety profile. The U.S. IDE pivotal study showed:

Adverse Events Cataract Surgery with iStent®
N=116 n (%)
Cataract Surgery Only
N=117 n (%)
Early postop corneal edema 9 (8%) 11 (9%)
Any BCVA loss of at least 1 line at or after the 3 month visit 8 (7%) 12 (10%)
Posterior capsular opacification 7 (6%) 12 (10%)
Stent obstruction 5 (4%) 0 (0%)
Blurry vision or visual disturbance 4 (3%) 8 (7%)
Elevated IOP 4 (3%) 5 (4%)

The iStent® procedure spares conjunctival tissue and preserves the potential for future treatment options. Additionally, there is minimal risk of hypotony with implantation of iStent® because the trabecular meshwork is preserved, ensuring a natural episcleral back-pressure of 8 to 11 mm Hg.

Important Safety Information »

Looking for more information on iStent®?

We’re here to answer questions and provide any additional information you may need.

Contact Us